Utah Retirement Systems Nektar Therapeutics Transaction History

Utah Retirement Systems

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $573,986 - $882,469	-34,661 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $22,078 - $26,642	1,400 Added 4.21%	34,661 $589,000
Q3 2020 Nov 16, 2020	BUY	$16.59 - $24.79 $4,977 - $7,437	300 Added 0.91%	33,261 $551,000
Q2 2020 Aug 13, 2020	BUY	$16.86 - $23.44 $16,860 - $23,440	1,000 Added 3.13%	32,961 $764,000
Q4 2019 Feb 12, 2020	BUY	$15.87 - $23.12 $3,174 - $4,624	200 Added 0.63%	31,961 $690,000
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $8,455 - $18,135	500 Added 1.6%	31,761 $579,000
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $17,639 - $20,654	569 Added 1.85%	31,261 $1.11 Million
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $50,275 - $73,789	1,592 Added 5.47%	30,692 $1.03 Million
Q4 2018 Feb 08, 2019	BUY	$30.43 - $56.65 $3,043 - $5,665	100 Added 0.34%	29,100 $957,000
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $4,646 - $6,848	100 Added 0.35%	29,000 $1.77 Million
Q2 2018 Aug 10, 2018	BUY	$46.25 - $104.45 $1.34 Million - $3.02 Million	28,900 New	28,900 $1.41 Million

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Utah Retirement Systems, based on Form 13F filings with the SEC.

Stay updated on Utah Retirement Systems with notifications on news.